Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular dystrophy victory lap

Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. At three years, the San Diego-based company’s cell therapy deramiocel improved patients’ left ventricular ejection fraction and ability to use their upper limbs.